Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Metastatic granulosa cell tumours and PARP inhibitors

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.07.18
Views: 683

Prof Isabelle Ray-Coquard - Centre Leon Berard, Lyon, France

Prof Ray-Coquard speaks with ecancer at BCGS about the importance of initial diagnosis and molecular analysis in the management of granulosa cell type ovarian cancers.

She also discusses clinical trials in this indication, including an upcoming presentation at ESMO 2018 on the first randomised trial for patients on weekly paclitaxel.

Prof Ray-Coquard also discusses the use of PARP inhibitors with antiangeogenic factors to treat ovarian cancers.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation